164 related articles for article (PubMed ID: 19118376)
1. Clinicobiological, prognostic and therapeutic implications of the tumor microenvironment in follicular lymphoma.
Lejeune M; Alvaro T
Haematologica; 2009 Jan; 94(1):16-21. PubMed ID: 19118376
[TBL] [Abstract][Full Text] [Related]
2. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols.
de Jong D; Koster A; Hagenbeek A; Raemaekers J; Veldhuizen D; Heisterkamp S; de Boer JP; van Glabbeke M
Haematologica; 2009 Jan; 94(1):70-7. PubMed ID: 19059937
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy.
Maeshima AM; Taniguchi H; Nomoto J; Miyamoto K; Fukuhara S; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Hum Pathol; 2013 Nov; 44(11):2529-35. PubMed ID: 23916290
[TBL] [Abstract][Full Text] [Related]
4. Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients.
Xerri L; Huet S; Venstrom JM; Szafer-Glusman E; Fabiani B; Canioni D; Chassagne-Clément C; Dartigues-Cuilléres P; Charlotte F; Laurent C; Gelas-Dore B; Bolen CR; Punnoose E; Bouabdallah R; Brice P; Morschhauser F; Cartron G; Olive D; Salles G;
Hum Pathol; 2017 Jun; 64():128-136. PubMed ID: 28414090
[TBL] [Abstract][Full Text] [Related]
5. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.
Blaker YN; Spetalen S; Brodtkorb M; Lingjaerde OC; Beiske K; Østenstad B; Sander B; Wahlin BE; Melen CM; Myklebust JH; Holte H; Delabie J; Smeland EB
Br J Haematol; 2016 Oct; 175(1):102-14. PubMed ID: 27341313
[TBL] [Abstract][Full Text] [Related]
6. Severe paraneoplastic pemphigus in a patient with follicular lymphoma.
Krogel C; Fischer T; Heidel F
Eur J Haematol; 2010 Apr; 84(4):365. PubMed ID: 19845742
[No Abstract] [Full Text] [Related]
7. CXCR4 expression during tumour cell death.
Skommer J; Wlodkowic D; Pelkonen J
Leuk Res; 2007 Aug; 31(8):1155-6. PubMed ID: 17064769
[No Abstract] [Full Text] [Related]
8. Rituximab chemotherapy regimens for treating advanced follicular lymphoma evaluated in new study.
Askeland G
Expert Rev Clin Immunol; 2013 May; 9(5):402. PubMed ID: 23772446
[No Abstract] [Full Text] [Related]
9. Prognostic factors in follicular lymphoma in the rituximab era: how to identify a high-risk patient?
Prochazka V; Papajik T; Jarosova M; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Jun; 155(2):99-108. PubMed ID: 21804618
[TBL] [Abstract][Full Text] [Related]
10. Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma.
Chin CK; Nastoupil LJ
Hematol Oncol Clin North Am; 2020 Aug; 34(4):743-756. PubMed ID: 32586578
[TBL] [Abstract][Full Text] [Related]
11. Implications of the tumor microenvironment on survival and disease response in follicular lymphoma.
Gribben JG
Curr Opin Oncol; 2010 Sep; 22(5):424-30. PubMed ID: 20679770
[TBL] [Abstract][Full Text] [Related]
12. Follicular Lymphoma: The Role of the Tumor Microenvironment in Prognosis.
Sugimoto T; Watanabe T
J Clin Exp Hematop; 2016; 56(1):1-19. PubMed ID: 27334853
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of SOCS3 is associated with decreased survival in a cohort of patients with de novo follicular lymphoma.
Krishnadasan R; Bifulco C; Kim J; Rodov S; Zieske AW; Vanasse GJ
Br J Haematol; 2006 Oct; 135(1):72-5. PubMed ID: 16939500
[TBL] [Abstract][Full Text] [Related]
14. New agents in follicular lymphoma.
Cheson BD
Best Pract Res Clin Haematol; 2011 Jun; 24(2):305-12. PubMed ID: 21658626
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of second rituximab maintenance after relapse in patients with follicular and mantle cell lymphoma.
Sanchez-Gonzalez B; Gimeno E; Garcia-Pallarols F; Ancochea A; Salar A
Leuk Lymphoma; 2014 Oct; 55(10):2384-6. PubMed ID: 24601815
[No Abstract] [Full Text] [Related]
16. Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma.
Desmots F; Roussel M; Pangault C; Llamas-Gutierrez F; Pastoret C; Guiheneuf E; Le Priol J; Camara-Clayette V; Caron G; Henry C; Belaud-Rotureau MA; Godmer P; Lamy T; Jardin F; Tarte K; Ribrag V; Fest T
Clin Cancer Res; 2019 Jan; 25(2):735-746. PubMed ID: 30348636
[TBL] [Abstract][Full Text] [Related]
17. The composition of the microenvironment in follicular lymphoma is associated with the stage of the disease.
Koch K; Hoster E; Unterhalt M; Ott G; Rosenwald A; Hansmann ML; Engelhard M; Hiddemann W; Klapper W
Hum Pathol; 2012 Dec; 43(12):2274-81. PubMed ID: 22795355
[TBL] [Abstract][Full Text] [Related]
18. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma.
Richendollar BG; Pohlman B; Elson P; Hsi ED
Hum Pathol; 2011 Apr; 42(4):552-7. PubMed ID: 21237493
[TBL] [Abstract][Full Text] [Related]
19. Hodgkin disease subsequent to follicular lymphoma on maintenance rituximab.
Scaramucci L; Perrotti A; Niscola P; Fratoni S; Palombi M; Piccioni D; Cupelli L; Tendas A; Dentamaro T; Del Poeta G; De Fabritiis P
Leuk Lymphoma; 2007 Sep; 48(9):1878-80. PubMed ID: 17786731
[No Abstract] [Full Text] [Related]
20. Primary follicular lymphoma of the GI tract: an increasingly recognized entity.
Jain VK; Bystricky B; Wotherspoon AC; Chau I; Cunningham D
J Clin Oncol; 2012 Dec; 30(36):e370-2. PubMed ID: 23150708
[No Abstract] [Full Text] [Related]
[Next] [New Search]
